seroreversion accounted for,test_id,source  (F=FDA testing/M=manufacturer [sometimes through FDA]/O = other),citation,test_name,sensitivity_estimate,sen_lower95CI,sen_upper95CI,number of COVID+ testing seropositive for sensitivity (TP),total number of COVID+ tested for sensitivity (TP + FN),specificity_estimate,spec_lower95CI,spec_upper95CI,number of COVID- testing seronegative for specificity (TN),total number of COVID- tested for specificity (TN + FP),notes
N/A (baseline),21-M,M,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Abbott Alinity i SARS-CoV-2 IgG nucleocapsid,100.0,89.9,100,34,34,99.0,94.6,99.8,99,100,
N/A (baseline),4-M,M,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Abbott Architect IgG,100.0,95.8,100,88,88,99.6,99.0,99.9,1066,1070,
N/A (baseline),4-O,O,https://thorax.bmj.com/content/75/12/1082,Abbott Architect IgG,90.8,85.6,94.5,167,184,99.8,98.9,100,499,500,
N/A (baseline),--  (M),M,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Abbott Alinity SARS-CoV-2 IgG II Quant,98.1,89.9,99.7,51,52,99.6,99.2,99.8,2000,2008,
N/A (baseline),--  (M),M,https://www.medrxiv.org/content/10.1101/2021.12.16.21267703v1.supplementary-material,Abingdon AbC-19 IgG anti-spike,98.03,95.03,99.46,199,203,99.56,98.4,99.95,448,450,
N/A (baseline),--  (O),O,https://link.springer.com/article/10.1007/s10096-021-04220-7,Acro Biotech IgG/IgM rapid test,96.0,,,24,25,81.0,,,17,21,
N/A (baseline),31-M,M,"https://www.amp-med.com/news-rapid-test-sars-cov-2  ,  https://www.finddx.org/product/amp-rapid-test-sars-cov-2-igg-igm/",AMP Rapid Test SARS-CoV-2 IgG/IgM,83,,,,,100,,,,,
N/A (baseline),31-O,O,https://sam.lrv.lt/uploads/sam/documents/files/KORONA/Serologini%C5%B3%20tyrim%C5%B3%20naudojimo%20rekomendacijos%20Versija_1.pdf (from n-25),AMP Rapid Test SARS-CoV-2 IgG/IgM,92.0,81.2,96.9,,,99.4,96.6,99.9,,,
N/A (baseline),101-M,M,https://www.beckmancoulter.com/products/immunoassay/access-sars-cov-2-igg-antibody-test,Beckman ACCESS SARS-CoV-2 anti-RBD,100,,,192,192,99.6,,,1395,1400,
N/A (baseline),101-M,M,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Beckman ACCESS SARS-CoV-2 anti-RBD,96.8,91.1,98.9,92,95,99.6,99.2,99.8,1395,1400,
N/A (baseline),66-M,M,https://www.monlab.es/document/Muestras%20suero-plasma/IFU%20Covid%2019%20Igg%20Igm%20TEST%20CASSETTE%20kewei.pdf,"Beijing Kewei Clinical Diagnostic, COVID-19 IgG IgM rapid cassette",91.8,,,,,96.4,,,,,
N/A (baseline),66-F,F,https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3338-a001.pdf,"Beijing Kewei Clinical Diagnostic, COVID-19 IgG IgM rapid cassette",93.3,78.7,98.2,28,30,91.2,83,95.7,73,80,
N/A (baseline),--  (M),-  (M),https://journals.asm.org/doi/full/10.1128/jcm.00075-22,Bernhard Nocht anti-nucleocapsid IgG ELISA #2,100.0,,,35,35,99.7,,,788,790,indirect ELISA
N/A (baseline),--  (M),M,https://www.medrxiv.org/content/10.1101/2021.12.16.21267703v1.supplementary-material,Biomerica anti-nucleocapsid IgG IgM rapid test,85.0,62.1,96.8,17,20,96.3,89.4,99.2,77,80,
N/A (baseline),--  (O),O,https://thorax.bmj.com/content/75/12/1082,Biomerica anti-nucleocapsid IgG IgM rapid test,81.0,74.7,86.4,149,184,97.8,96.1,98.9,489,500,
N/A (baseline),22-M,M,https://www.fda.gov/media/137493/download,BioRad Platelia Total Antibody nucleocapsid,98.0,,,49,50,99.3,,,596,600,
N/A (baseline),65-M,M,https://academic.oup.com/jid/article/222/2/189/5831993,Bioscience 2019-nCoV IgM and IgG,81.5,,,225,276,100,,,176,176,
N/A (baseline),--  (M),M,https://www.apodan.dk/media/2387/ifu_sw40005a_en_v04202007r02.pdf,Biosynex COVID-19 IgM IgG,100.0,,,456,456,98.1,,,457,466,
N/A (baseline),--  (O),O,https://www.apodan.dk/media/2387/ifu_sw40005a_en_v04202007r02.pdf,Biosynex COVID-19 IgM IgG,100,,,39,39,100,,,40,40,
N/A (baseline),--  (M),M,https://www.medrxiv.org/content/10.1101/2021.12.16.21267703v1.supplementary-material,Biozek COVID-19 IgG/IgM rapid test,100,86.0,100,20,20,98.0,89.4,99.9,49,50,
N/A (baseline),100-M,M,"n-264 (for ""at least 2 out of 3 antigens"" and table 1)",CCAHS ELISA anti-spike anti-RBD anti-nucleocapsid (positive on at least 2 out of 3),91,,,357,392,100.0,,,560,560,
N/A (baseline),--  (M),M,https://testecovid19.org/wp-content/uploads/2018/10/Bula-Cellex.pdf,Cellex IgG/IgM rapid test,93.8,,,120,128,96.0,,,240,250,
N/A (baseline),62-M,M,https://www.cordx.com/product/covid-19-igm-igg-ab-test/,Coretest COVID-19 IgM/IgG Ab Test (Core Technology),91.0,83.6,95.8,91,100,99.0,96.4,99.9,198,200,
N/A (baseline),62-O,O,https://www.medrxiv.org/content/10.1101/2021.05.08.21256893v1.full,Coretest COVID-19 IgM/IgG Ab Test (Core Technology),79.45,,,58,73,100,,,222,222,
N/A (baseline),74-M,M,"https://ablediagnostics.com/prods/docs/2-IFU.pdf  [tables 1, 2, 5, and 6]","COVID-19 IgG/IgM ECO Test (not the ""Combo"" test; Eco Diagnostica)",100,,,62,62,99.1,,,216,218,
N/A (baseline),74-F,F,via: https://ablediagnostics.com/prods/docs/2-IFU.pdf  [table 4],"COVID-19 IgG/IgM ECO Test (not the ""Combo"" test; Eco Diagnostica)",100,88.7,100,30,30,98.8,,,79,80,
N/A (baseline),74-O,O,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544564/,"COVID-19 IgG/IgM ECO Test (not the ""Combo"" test; Eco Diagnostica)",75.1,68.2,80.9,130,173,99.1,95.2,99.8,115,116,
N/A (baseline),50-M,M,https://pubmed.ncbi.nlm.nih.gov/33444413/,COVIDAR anti-spike anti-RBD,87.2,,,252,289,100.0,,,277,277,
N/A (baseline),75-M,M,https://drive.google.com/file/d/1ATIHN4yKm_X9GPgJZER46e9YSJZfuO6R/view  [ https://archive.ph/3yma6 ],CTK Biotech Onsite COVID 19 IgG/IgM rapid test kit,97.1,93.9,98.7,204,210,97.8,95.2,99.0,264,270,
N/A (baseline),75-F,F,https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3355-a001.pdf,CTK Biotech Onsite COVID 19 IgG/IgM rapid test kit,100,88.7,100,30,30,98.8,93.3,99.8,79,80,
N/A (baseline),15-M,M,https://www.diasorin.com/sites/default/files/allegati/liaisonr_sars-cov-2_s1s2_igg_brochure.pdf.pdf,Diasorin Liaison S1/S2 spike IgG,97.4,86.8,99.5,38,39,99.3,98.6,99.6,1082,1090,
N/A (baseline),15-O,O,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/893435/Evaluation_of_Diasorin_Liaison_anti_SARS_CoV_2.pdf,Diasorin Liaison S1/S2 spike IgG,76.5,,,65,85,,,,489,499,equivocal results included with positives
N/A (baseline),--  (M),M,https://ptgenetika.com/wp-content/uploads/2020/03/Pack-insert-DNK-1419-1-2019-nCOV-IgG-IgM-Rapid-Test.pdf,Dynamiker IgG/IgM rapid test,93.2,,,151,162,95.3,,,286,300,
N/A (baseline),12-M,M,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM,99.5,97,100,185,186,99.80,99.69,99.88,10432,10453,
N/A (baseline),12-M,M,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM,100,88.3,100,29,29,99.8,99.7,99.9,5262,5272,
N/A (baseline),12-O,O,https://onlinelibrary.wiley.com/doi/10.1002/jmv.27126,Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM,89.1,76.4,96.4,41,46,,,,,,
N/A (baseline),17-M,M,https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2-s.html,Elecsys Anti-SARS-CoV-2 Roche spike,98.8,98.1,99.3,1406,1423,100.0,,,7090,7091,
N/A (baseline),--  (M),M,https://static1.squarespace.com/static/52545951e4b021818110f9cf/t/5fcebf83ca1f943ff5a447c3/1607384968098/KT-1032+RUO+V6+2020-12.pdf,EDI Novel coronavirus COVID19 IgG anti-nucleocapsid,98.4,95.4,99.5,184,187,99.8,99.1,99.97,623,624,
N/A (baseline),46-M,M,"n-253 , https://www.nature.com/articles/s41598-020-76913-6#Sec14  (figure S7)",Enable’s ADAP SARS-CoV-2 total antibody anti-nucleocapsid,,,,20,20,,,,100,100,
N/A (baseline),48-M,M,https://www.nature.com/articles/s41598-020-76913-6#Sec14,Enable’s ADAP SARS-CoV-2 total antibody anti-spike,100,89,100,31,31,100,95,100,80,80,
N/A (baseline),--  (M),M,https://erbalisacovid19.erbamannheim.com/getattachment/Home/image-content/Covid/ErbaLisa-COVID-19-IgG_flyer.pdf.aspx?lang=en-US&ext=.pdf,ERBALISA COVID-19 IgG,98.3,,,57,58,98.1,,,105,107,
N/A (baseline),--  (O),O,https://academic.oup.com/trstmh/advance-article/doi/10.1093/trstmh/trab109/6335791,ERBALISA COVID-19 IgG,99.12,,,,,99.33,,,,,
N/A (baseline),--  (M),M,https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_C.pdf,Euroimmun anti-nucleocapsid IgG IgM,94.6,,,53,56,99.8,,,1245,1248,
N/A (baseline),6-M,M,https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_C.pdf,Euroimmun anti-spike,94.4,,,68,72,99.6,,,1362,1367,
N/A (baseline),1-O,O,"n-14 , https://thorax.bmj.com/content/75/12/1082 [table 2 (finger-prick only)]","Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)",84.4,70.5,93.5,38,45,98.6,97.1,99.4,493,500,
N/A (baseline),78-M,M,https://pass.genetico.ru/,Genetico CoronaPass total antibodies test for spike,95.7,,,90,94,97.6,,,444,455,
N/A (baseline),78-O,O,https://onlinelibrary.wiley.com/doi/10.1002/jmv.27126,Genetico CoronaPass total antibodies test for spike,91.1,78.8,97.5,42,46,100,91.6,100,41,41,
N/A (baseline),--  (M),M,https://www.genscript.com/gsfiles/techfiles/GS-SOP-CPTS001G-05_L00847-C.pdf?651186757  [page 12],GenScript cPass neutralization kit,96.7,,,29,30,96.7,,,58,60,
N/A (baseline),--  (M) [send via FDA],M,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,GenScript cPass neutralization kit,100,87.1,100,26,26,100,95.8,100,88,88,
N/A (baseline),28-M,M,https://pellecome.com/wp-content/uploads/2020/03/ClungeneIFU-Amended.pdf,Hangzhou Clongene IgM/IgG rapid test,87.0,,,67,77,98.9,,,89,90,
N/A (baseline),10-M,M,https://sa1s3.patientpop.com/assets/docs/240677.pdf,Healgen COVID-19 IgG/IgM rapid test cassettes,96.7,90.7,98.9,87,90,97.0,,,98,101,
N/A (baseline),10-F,F,via: https://sa1s3.patientpop.com/assets/docs/240677.pdf,Healgen COVID-19 IgG/IgM rapid test cassettes,100,88.7,100,30,30,97.5,91.3,99.3,78,80,
N/A (baseline),--  (M),M,https://www.immundiagnostik.com/media/pages/testkits/k-5004/e859ef5a82-1647309682/k5004_2021-08-10_idk_sars-cov-2-igg.pdf  [page 10],IDK (Immundiagnostik) anti-spike IgG,100,,,30,30,99.1,,,755,762,
N/A (baseline),--  (M),M,https://inbios.com/wp-content/uploads/2021/05/LBL-0113-03-EUA-CE-SCoV-2-Detect-IgG-ELISA-product-insert-English.pdf,InBios SCoV-2 Detect IgG anti-spike ELISA,98.5,,,66,67,98.9,94.3,99.8,94,95,
N/A (baseline),--  (F),F,via: https://inbios.com/wp-content/uploads/2021/05/LBL-0113-03-EUA-CE-SCoV-2-Detect-IgG-ELISA-product-insert-English.pdf,InBios SCoV-2 Detect IgG anti-spike ELISA,100,88.7,100,30,30,100,95.4,100,80,80,
N/A (baseline),60-M,M,https://eurofinsgenomics.eu/media/1611049/technical-sheet-ingezim-covid-19-dr-030620_en.pdf,INgezim COVID 19 DR Test,92.6,,,150,162,98.3,,,114,116,
N/A (baseline),60-O,O,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521368/,INgezim COVID 19 DR Test,90.1,,,64,71,91.07,,,51,56,
N/A (baseline),--  (M),M,https://assets.researchsquare.com/files/rs-1317280/v2/d5989c78-d104-4e93-9a01-7ac984b019dd.pdf?c=1643999039,in-house ELISA for N protein and S protein from IPT (Institut Pasteur in Tunis),95.4,,,103,108,93.1,,,67,72,
N/A (baseline),102-M,M,https://www.nature.com/articles/s41598-021-97423-z  [n-287],in-house Jefferson County anti-spike IgG,100,,,38,38,98.8,,,79,80,
N/A (baseline),70-M,M,https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyab217/6414575?rss=1  [n-99],in-house Luminex S protein trimer IgG,100.0,,,15,15,100,,,31,31,
N/A (baseline),37-M,M,https://journals.asm.org/doi/epub/10.1128/Spectrum.01131-21,in-house THL Finland FMIA anti-spike assay,100.0,97.3,100,140,140,100,99.1,100,402,402,
N/A (baseline),--  (M),M,https://journals.asm.org/doi/epub/10.1128/Spectrum.01131-21 [figure 5],in-house THL Finland neutralization assay,92.5,,,37,40,,,,,,
N/A (baseline),--  (M),M,https://www.frontiersin.org/articles/10.3389/fmicb.2020.618097/full [Mehdi et al.],in-house RBD ELISA (Mehdi et al.),84.7,,,238,281,99.8,,,469,470,
N/A (baseline),--  (M),M,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530443/,Kavach-AntiSARS-CoV-2 IgG ELISA (Zydus),92.4,,,121,131,97.9,,,374,382,
N/A (baseline),--  (O),O,https://academic.oup.com/trstmh/advance-article/doi/10.1093/trstmh/trab109/6335791,Kavach-AntiSARS-CoV-2 IgG ELISA (Zydus),92.1,,,,,97.7,,,,,
,,,"n-218 , https://www.labcorp.com/tests/164055/sars-cov-2-antibody-igg",LabCorp SARS-CoV-2 semi-quantitative IgG anti-spike,,,,,,,,,,,
N/A (baseline),7-M,M,http://www.livzondiagnostics.com/en-us/info/17.html,Livzon COVID-19 IgG IgM lateral flow,90.6,,,259,286,99.2,,,355,358,
N/A (baseline),7-F,F,https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3285-a001.pdf,Livzon COVID-19 IgG IgM lateral flow,86.7,70.3,94.7,26,30,97.5,91.3,99.3,78,80,
N/A (baseline),--  (M),M,https://tetracore.com/wp-content/uploads/2021/04/FlexImmArraySARS-CoV-2IgGkitIFU_ver05122020_web.pdf,Luminex Tetracore FlexImmArray S NP,100.0,,,43,43,100.0,,,308,308,
N/A (baseline),--  (O),O,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241621/,Luminex Tetracore FlexImmArray S NP,,,,,,,,,,,
N/A (baseline),34-M,M,"n-174 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Luminex xMAP for spike and nucleocaspid (Los Angeles study used RBD portion),96.3,,,79,82,99.3,98.3,99.7,599,603,
N/A (baseline),--  (M),M,https://www.lumiradx.com/us-en/test-menu/antibody-test,LumiraDx SARS-CoV-2 anti-spike antibody test,100,,,57,57,100,,,53,53,
N/A (baseline),--  (F),F,via: https://www.lumiradx.com/assets/pdfs/covid-19-antibody-test/sars-cov-2-antibody-ab-product-insert/sars-cov-2-ab-product-insert-eua.pdf?v=1,LumiraDx SARS-CoV-2 anti-spike antibody test,100,,,30,30,100,,,80,80,
N/A (baseline),--  (O),O,https://www.lumiradx.com/assets/pdfs/covid-19-antibody-test/sars-cov-2-antibody-ab-product-insert/sars-cov-2-ab-product-insert-eua.pdf?v=1,LumiraDx SARS-CoV-2 anti-spike antibody test,100,,,55,55,100,98.7,100,290,290,
N/A (baseline),27-M,M,https://wwwnc.cdc.gov/eid/article/27/6/21-0568_article,"Massachusetts General Hospital, anti-spike ELISA",65.5,,,655,1000,100.0,,,104,104,
N/A (baseline),--  (M),M,https://www.mikrogen.de/english/products/product-overview/testsystem/sars-cov-2-igg-aviditaet-ruo.html,Mikrogen GmbH recomLine SARS-CoV-2 IgG,97.9,,,46,47,99.8,,,570,571,
N/A (baseline),35-M,M,n-178,Mount Sinai RBD ELISA (New York),96.8,,,122,126,94.1,,,,,
N/A (baseline),19-M,M,n-138,"Netherlands, in-house anti-spike assay",91.6,,,,,99.7,,,,,
N/A (baseline),--,#N/A,,Obolensk ELISA anti-nucleocapsid IgG (State Scientific Center of Applied Microbiology and Biotechnology),,,,,,,,,,,
N/A (baseline),3-M,M,http://www.bvs.hn/COVID-19/Plataforma/OrientGene_INSERTO.pdf,Orient Gene Biotech COVID-19 IgG/IgM Rapid Test,87.9,,,87,99,100,,,14,14,
N/A (baseline),3-O,O,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383543/,Orient Gene Biotech COVID-19 IgG/IgM Rapid Test,95.8,89.6,98.8,91,95,100.0,93.4,100,42,42,
N/A (baseline),--,M,https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-igg-igm-antibody-test.html  [ https://ensur.invmed.com/ensur/contentAction.aspx?key=ensur.519138.S2R4E4A3.20200413.450.3904912 ],Panbio IgG/IgM rapid test,96.2,80.4,99.9,25,26,100.0,85.8,100,24,24,
N/A (baseline),--,O,https://www.sciencedirect.com/science/article/pii/S1386653220303875,Panbio IgG/IgM rapid test,98.2,,,107,109,99.4,,,149,150,
N/A (baseline),--  (F),F,https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3286-a001.pdf,PCL COVID-19 IgG/IgM Rapid Gold,96.7,83.3,99.4,29,30,100,94.8,100,70,70,
N/A (baseline),77-O,O,https://www.medrxiv.org/content/10.1101/2021.03.12.21253442v2.full,Pishtaz Teb SARS-CoV-2 ELISA kits (for nucleocapsid),74,67,80,188,254,98,96,99,402,410,
N/A (baseline),44-M,M,https://premierbiotech.com/innovation/wp-content/uploads/2020/12/Attachment-1_06_clean-version-Proposed-Premier-Biotech-IFU-with-POC-fingerstick-12212020.pdf,Premier Biotech COVID-19 IgG/IgM Rapid Test anti-RBD,88.2,72.6,96.7,30,34,100,91.1,100,32,32,alternative source: https://academic.oup.com/ije/article/50/2/410/6146069#247859055  [section S2]
N/A (baseline),44-F,F,via: https://premierbiotech.com/innovation/wp-content/uploads/2020/12/Attachment-1_06_clean-version-Proposed-Premier-Biotech-IFU-with-POC-fingerstick-12212020.pdf,Premier Biotech COVID-19 IgG/IgM Rapid Test anti-RBD,100,88.7,100,30,30,100,95.4,100,80,80,alternative source: https://academic.oup.com/ije/article/50/2/410/6146069#247859055  [section S2]
N/A (baseline),44-O,O,https://academic.oup.com/ije/article/50/2/410/6146069#247859055  [section S2],Premier Biotech COVID-19 IgG/IgM Rapid Test anti-RBD,85.56,79.69,90.26,,,99.53,99.24,99.73,,,
N/A (baseline),--,M,https://www.medica.de/vis-content/event-medcom2020.MEDICA/exh-medcom2020.2677845/MEDICA-2020-QINGDAO-HIGHTOP-BIOTECH-CO.-LTD-Product-medcom2020.2677845-2ChZsL7lSdS2p9Huhl7udg.pdf,Qingdao Hightop IgG/IgM one step rapid test,94.1,,,193,205,93.9,,,324,345,
N/A (baseline),--,O,https://www.sciencedirect.com/science/article/pii/S1201971220322116,Qingdao Hightop IgG/IgM one step rapid test,59.5,51.4,67.1,,,100.0,96.8,100,,,
N/A (baseline),--,O,http://www.mjpath.org.my/2020/v42n1/COVID-19-serology.pdf,Qingdao Hightop IgG/IgM one step rapid test,93.0,,,279,300,96.0,,,960,1000,
N/A (baseline),--  (M),M,https://www.fda.gov/media/138660/download,RightSign IgG/IgM rapid test,96.2,92.0,98.3,152,158,98.1,95.1,99.3,206,210,
N/A (baseline),--  (F),F,https://www.fda.gov/media/138660/download,RightSign IgG/IgM rapid test,100.0,88.7,100,30,30,100.0,95.4,100,80,80,
N/A (baseline),--  (M),M,https://www.medrxiv.org/content/10.1101/2021.12.16.21267703v1.supplementary-material,Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM,99.03,94.71,99.98,102,103,98.65,96.1,99.72,219,222,
N/A (baseline),26-M,M,https://journals.asm.org/doi/10.1128/JVI.01828-20,SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological),96.6,,,28,29,99.7,,,363,364,cited in: https://link.springer.com/article/10.1007/s00038-020-01494-0
N/A (baseline),--  (M),M,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Siemens Advia SARS-CoV-2 IgG anti-RBD,95.6,92.3,97.5,238,249,99.9,99.6,100,1993,1995,
N/A (baseline),--  (M),M,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/sars-cov-2-igg-assay,Siemens Advia SARS-CoV-2 IgG anti-RBD,96.41,,,,,99.90,,,1993,1995,
N/A (baseline),59-M,M,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Siemens SARS-CoV-2 Total Advia Centaur,100,92.4,100,47,47,99.8,99.4,99.9,1586,1589,
N/A (baseline),59-M,M,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/cov2t-assay,Siemens SARS-CoV-2 Total Advia Centaur,98.73,,,,,99.81,,,,,
N/A (baseline),39-M,M,n-169 (main text and table S1),Sinai Health (Toronto) anti-spike ELISA,95.5,,,384,402,99.12,,,,339,
N/A (baseline),40-M,M,n 203 (supplemental material),"Sinai Health (Toronto) anti-spike anti-RBD anti-nucleocapsid ELISA, lenient cutoff",98,,,95,97,99,,,89,90,
N/A (baseline),51-M,M,https://www.ncbi.nlm.nih.gov/books/NBK572322/bin/fdacovideuas_142233.pdf,SNIBE Maglumi spike nucleocapsid IgG IgM ,100.0,97.4,100.0,142,142,98.7,96.2,99.5,223,226,also at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance
N/A (baseline),61-M,M,https://drive.google.com/file/d/1yQvJf7_nDxIvdOFkuwppxs8b6G4hCHbG/view?usp=sharing,Standard Q COVID-19 IgM/IgG Plus,97.7,,,130,133,98.7,,,148,150,
N/A (baseline),--  (M),M,https://www.fda.gov/media/140297/download,Standard Q IgM/IgG Combo,98.2,,,55,56,99.5,,,368,370,
N/A (baseline),--  (F),F,https://www.fda.gov/media/140297/download,Standard Q IgM/IgG Combo,100.0,88.7,100,30,30,95.0,87.8,98,76,80,
N/A (baseline),--  (M),M,"https://validahealth.dk/wp-content/uploads/2020/09/valida-health-antibody-test-details-sheet.pdf  ,  https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07031-z  [n-150]","Techno Genetics anti-RBD, nCOVID-19 IgG/IgM POCT (point-of-care test)",94.6,,,35,37,99.3,,,270,272,
N/A (baseline),9-M,M,"https://cdn.shopify.com/s/files/1/0094/4698/1732/files/POCT_-_VR-11_Clinical_Study.pdf?v=1591354196 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038148/","Techno Genetics, Rapid Test SARS-CoV-2 IgM/IgG Gold, anti-nucleocapsid",94.6,,,35,37,98.9,,,269,272,
N/A (baseline),--  (M),M,https://www.frontiersin.org/articles/10.3389/fmicb.2020.628281/full,Tosoh anti-spike IgG with AIA-CL1200 ,100,97.6,100,153,153,100,99.63,100,1000,1000,
N/A (baseline),--  (M),M,https://www.frontiersin.org/articles/10.3389/fmicb.2020.628281/full,Tosoh anti-nucleocapsid IgG with AIA-CL1200 ,100,97.6,100,153,153,100,99.63,100,1000,1000,
N/A (baseline),--  (M),M,https://www.frontiersin.org/articles/10.3389/fmicb.2020.628281/full,Tosoh anti-spike total Ig with AIA-CL1200 ,100,97.6,100,153,153,100,99.63,100,1000,1000,
N/A (baseline),48-M,M,https://www.frontiersin.org/articles/10.3389/fmicb.2020.628281/full,Tosoh anti-nucleocapsid total Ig with AIA-CL1200 ,100,97.6,100,153,153,100,99.63,100,1000,1000,
N/A (baseline),--  (M),M,https://www.antibodies.com/datasheets/UNscience/UNCOV-40.pdf,UNCOV-40 IgG/IgM,98.8,97.3,99.6,416,421,98.0,97.1,98.7,1141,1164,
N/A (baseline),76-M,M,https://www.medrxiv.org/content/10.1101/2020.07.13.20152884v6.full.pdf,University of Rio de Janeiro (UFRJ) anti-spike ELISA,95,,,344,362,98.6,,,142,144,
N/A (baseline),2-M,M,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext,"University of Oxford, IgG for spike",99.1,97.9,99.7,535,540,99.0,98.0,100.0,967,977,Oxford assay (from the Target Discovery Institute) assay is excluded for list of external commerical assays in table S2
N/A (baseline),--  (O),O,https://onlinelibrary.wiley.com/doi/10.1002/jmv.27126,Vector-Best SARS-CoV-2-IgG-ELISA-Best,89.1,76.4,96.4,41,46,100,91.4,100.0,41,41,
N/A (baseline),57-M,M,https://www.orthoclinicaldiagnostics.com/assets/images/AABB%20IgG%20Poster.pdf,Vitros Ortho (not total) IgG anti-spike,90.0,76.9,96.0,36,40,100,99.1,100.0,407,407,
N/A (baseline),13-M,M,"https://techdocs.ocdx.com/ [search for: ""Anti-SARS-CoV-2 Total"" among ""Reagent Instructions for Use""]  ;  also at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Vitros Ortho total Ig anti-spike,100,92.7,100,49,49,100,99,100,400,400,
N/A (baseline),--  (M),M,"https://consultas.anvisa.gov.br/api/consulta/produtos/25351200980202041/anexo/T12118646/nomeArquivo/Instru%C3%A7%C3%B5es%20de%20Uso_Rev%2001.pdf?Authorization=Guest 
 [ https://www.scielo.br/j/bjid/a/DZYQCFQg7WZhr49z7gTdKSK/?format=pdf&lang=en ]",Vyttra Smart Test COVID-19,100,,,,4,100,,,,6,test info: https://consultas.anvisa.gov.br/api/consulta/produtos/25351200980202041/anexo/T12118646/nomeArquivo/Instru%C3%A7%C3%B5es%20de%20Uso_Rev%2001.pdf?Authorization=Guest
N/A (baseline),8-M,M,https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf,"Wantai ELISA, SARS-CoV-2 total antibody, IgG IgM (against RBD)",94.4,,,251,266,100.0,,,306,306,
N/A (baseline),8-F,F,"https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance  ,  https://www.fda.gov/media/140929/download","Wantai ELISA, SARS-CoV-2 total antibody, IgG IgM (against RBD)",96.7,,,29,30,97.5,,,78,80,
N/A (baseline),8-O,O,https://www.fda.gov/media/140929/download,"Wantai ELISA, SARS-CoV-2 total antibody, IgG IgM (against RBD)",98.7,93.1,99.8,77,78,98.6,,,494,501,
N/A (baseline),103-M,M,http://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-Rapid-Test.pdf,"Wantai rapid test, SARS-CoV-2 total antibody, IgG IgM (against RBD)",94.7,,,125,132,98.9,,,268,271,
N/A (baseline),103-F,F,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Wantai rapid test, SARS-CoV-2 total antibody, IgG IgM (against RBD)",100,88.7,100,30,30,98.8,93.3,99.8,79,80,
N/A (baseline),104-M,M,"n-29 , n-297",YHLO iFlash SARS CoV-2 (spike + nucleocapsid),97.3,,,,,96.3,,,,,
N/A (baseline),104-O,O,https://www.ijidonline.com/article/S1201-9712(20)30198-3/fulltext,YHLO iFlash SARS CoV-2 (spike + nucleocapsid),88.9,,,24,27,90.9,,,30,33,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
Yes,100,,n-14,"REACT-2, phase 1: Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)",81.2,,,277,341,98.6,97.1,99.4,493,500,
Yes,101,,"n-102 , n-14","REACT-2, phase 2: Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)",76.1,,,274,360,98.6,97.1,99.4,493,500,
Yes,102,,"n-102 , n-14","REACT-2, phase 3: Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)",63.2,,,474,750,98.6,97.1,99.4,493,500,
Yes,103,,"n-15 , n-14","REACT-2, phase 4: Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)",62.0,,,1094,1765,98.6,97.1,99.4,493,500,
Not yet,104,,n-14,"REACT-2, phase 5: Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)",,,,,,98.6,97.1,99.4,493,500,
Not yet,105,,n-14,"REACT-2, phase 6: Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)",,,,,,98.6,97.1,99.4,493,500,
Not yet,200,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","BioBank, phase 1: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,201,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","BioBank, phase 2: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,202,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","BioBank, phase 3: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,203,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 1: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,204,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 2: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,205,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 3: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,206,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 4: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,207,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 5: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,208,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 6: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,209,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 7: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,210,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 8: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,211,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 9: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,212,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 10: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,213,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 11: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,214,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 1: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,215,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 2: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,216,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 3: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,217,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 4: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,218,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 5: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,219,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 6: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,220,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 7: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,221,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 8: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,222,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 9: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,223,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 1: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,224,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 2: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,225,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 3: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,226,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 4: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,227,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 5: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,228,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 6: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,229,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 7: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,230,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 8: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,231,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 1: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,232,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 2: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,233,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 3: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,234,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 4: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,235,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 5: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,236,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 6: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,237,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 7: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,238,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 8: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,239,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 10: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,240,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 12: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,241,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 13: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,242,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 9: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,243,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 10: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,244,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 9: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,245,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 10: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,246,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","BioBank, phase 4: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,247,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","BioBank, phase 5: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,248,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 11: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,249,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 12: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,250,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 13: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,251,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 14: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,252,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 15: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,253,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Wales, phase 16: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,254,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 11: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,255,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 12: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,256,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Scotland, phase 13: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,257,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 11: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,258,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 12: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,259,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 13: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,260,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 14: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,261,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS Northern Ireland, phase 15: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,262,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 14: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,263,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 15: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,264,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 16: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,265,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 17: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,266,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 18: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,267,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 19: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,268,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 20: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Not yet,269,,"n-117 (page 15) , https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30634-4/fulltext","ONS England, phase 21: University of Oxford, IgG for spike",,,,,,99.0,98.0,100.0,967,977,
Yes,300,,n-44,"Spain, phase 1: Orient Gene Biotech COVID-19 IgG/IgM Rapid Test",88.7,,,189,213,99.0,,,102,103,
Yes,301,,"n-104 , n-44","Spain, phase 2: Orient Gene Biotech COVID-19 IgG/IgM Rapid Test",76.7,,,276,360,99.0,,,102,103,
Yes,302,,"n-104 , n-44","Spain, phase 3: Orient Gene Biotech COVID-19 IgG/IgM Rapid Test",74.1,,,341,460,99.0,,,102,103,
Yes,303,,"n-45 , n-44","Spain, phase 4: Orient Gene Biotech COVID-19 IgG/IgM Rapid Test",64.0,,,1137,1777,99.0,,,102,103,
Not yet,400,,"n-53 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Castiglione D'Adda: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Yes,401,,"n-10 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Utah, 4 counties, phase 1: Abbott Architect IgG",83.3,,,25,30,99.6,99.0,99.9,1066,1070,
Not yet,402,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Verona: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,403,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Indiana, phase 1: Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,404,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Ascension, East Baton Rouge, Livingston, + West Baton Rouge Parishes: Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,405,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Jefferson and Orleans parishes: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,406,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Rhode Island: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,407,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Italy: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,408,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Trento (5 municipalities): Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,409,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Val Gardena (Ortisei, Santa Cristina, Selva): Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,410,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,South Tyrol (excluding Val Gardena): Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,411,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Wisconsin, phase 1: Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,412,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Wisconsin, phase 2: Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,413,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Wisconsin, phase 3: Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,414,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Indiana, phase 2: Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,415,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Nevada, Washoe County: Abbott Architect IgG",,,,,,99.6,99.0,99.9,1066,1070,
Not yet,416,,"n-10 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Cache County: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,417,,"n-10 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Washington County: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Not yet,418,,"n-10 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Weber County: Abbott Architect IgG,,,,,,99.6,99.0,99.9,1066,1070,
Yes,500,,"n-29 , https://link.springer.com/article/10.1007%2Fs15010-020-01503-7","Tirschenreuth district, analysis of: in-house RBD ELISA + Elecsys Anti-SARS-CoV-2 Roche nucleocapsid  +  YHLO iFlash SARS CoV-2 (spike + nucleocapsid)  ",93.9,,,62,66,99.3,,,993,1000,
Yes,600,,"n-31 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Grand Est, Île-de-France, Nouvelle-Aquitaine; phase 1: Euroimmun anti-spike",87.2,,,68,78,100,95.4,100,80,80,
Yes,601,,"n-26 (page 20) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Aachen (phase 1): Euroimmun anti-spike,64.3,,,9,14,100,95.4,100,80,80,
Yes,602,,"n-26 (page 20) , n-173 (eSupplement-Table 3) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Aachen, unvaccinated (phase 2): Euroimmun anti-spike",87.1,,,61,70,100,95.4,100,80,80,
Yes,603,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Germany, national (SOEP): Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,604,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Geneva, phase 1: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,605,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Geneva, phase 2: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Yes,606,,"n-149 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","France, phase 1: Euroimmun anti-spike",89.2,,,74,83,100,95.4,100,80,80,
Not yet,607,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"France, phase 2: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,608,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Norway: Euroimmun anti-spike,,,,,,100,95.4,100,80,80,
Not yet,609,,"n-31 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Grand Est, Île-de-France, Nouvelle-Aquitaine; phase 2: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,610,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Osnabrück district, phase 2: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,611,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Magdeburg, phase 2: : Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,612,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Vorpommern-Greifswald, phase 1: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,613,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Chemnitz, phase 1: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,614,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Chemnitz, phase 2: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Not yet,615,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Salt Lake County, phase 4: Euroimmun anti-spike",,,,,,100,95.4,100,80,80,
Yes,616,,"n-295 (tabelle 3 on page 25)  ,  https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Germany, Straubing: Euroimmun anti-spike",53.1,,,17,32,100,95.4,100,80,80,
Yes,617,,"n-295 (tabelle 3 on page 25)  ,  n-236  ,  https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Germany, Mitte (in Berlin): Euroimmun anti-spike",60.0,,,21,35,100,95.4,100,80,80,
Yes,618,,"n-26 (page 20) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Freiburg + Breisgau-Hochschwarzwald (phase 1): Euroimmun anti-spike,75.0,,,12,16,100,95.4,100,80,80,
Yes,619,,"n-26 (page 20) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Magdeburg (phase 1): Euroimmun anti-spike,92.9,,,26,28,100,95.4,100,80,80,
Yes,620,,"n-26 (page 20) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Osnabrück district + Osnabrück city (phase 1): Euroimmun anti-spike,64.7,,,11,17,100,95.4,100,80,80,
Yes,621,,"n-26 (page 20) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Reutlingen (phase 1): Euroimmun anti-spike,90.9,,,10,11,100,95.4,100,80,80,
Yes,622,,"n-26 (page 20) , n-173 (eSupplement-Table 3) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Freiburg + Breisgau-Hochschwarzwald (phase 2): Euroimmun anti-spike,90.9,,,10,11,100,95.4,100,80,80,
Yes,623,,"n-26 (page 20) , n-173 (eSupplement-Table 3) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Reutlingen (phase 2): Euroimmun anti-spike,81.0,,,17,21,100,95.4,100,80,80,
Yes,624,,"n-26 (page 20) , n-173 (eSupplement-Table 3) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Magdeburg, unvaccinated (phase 2): Euroimmun anti-spike",82.5,,,33,40,100,95.4,100,80,80,
Yes,625,,"n-26 (page 20) , n-173 (eSupplement-Table 3) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Osnabrück district + Osnabrück city (phase 2): Euroimmun anti-spike,91.9,,,34,37,100,95.4,100,80,80,
Yes,626,,"n-26 (page 20) , n-173 (eSupplement-Table 3) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Chemnitz, unvaccinated (phases 1 + 2): Euroimmun anti-spike",85.6,,,220,257,100,95.4,100,80,80,
Yes,627,,"n-26 (page 20) , n-173 (eSupplement-Table 3) , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance","Vorpommern-Greifswald, unvaccinated: Euroimmun anti-spike",81.4,,,70,86,100,95.4,100,80,80,
Yes,700,,"n-43  ,  http://www.livzondiagnostics.com/en-us/info/17.html","Andorra, phase 1: Livzon COVID-19 IgG IgM lateral flow ",80.7,,,305,378,99.2,,,355,358,
Yes,701,,"n-105 (supplementary figure 7 [samples on day 21 or later])  ,  http://www.livzondiagnostics.com/en-us/info/17.html",Denmark (We Test): Livzon COVID-19 IgG IgM lateral flow ,25.1,,,162,645,99.2,,,355,358,
Yes,800,,"n-22  ,  https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ","Denmark (SSI), phases 1 - 4: Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",93.5,,,217,232,100.0,,,306,306,
Yes,801,,"n-194  ,  https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ","Denmark (SSI), phase 5: Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",94.2,,,484,514,100.0,,,306,306,
Yes,802,,"n-195  ,  https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ","Denmark (SSI), phase 6: Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",91.0,,,282,310,100.0,,,306,306,
Yes,803,,"n-284 (table 3)  ,  https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ","Brussels, Flanders, and Wallonia (phases 1-5): Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",68.7,,,,103,100.0,,,306,306,sensitivity is population-weighted
Not yet,804,,https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ,"Brussels, Flanders, and Wallonia (phase 1): Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",,,,,,100.0,,,306,306,
Not yet,805,,https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ,"Brussels, Flanders, and Wallonia (phase 2): Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",,,,,,100.0,,,306,306,
Not yet,806,,https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ,"Brussels, Flanders, and Wallonia (phase 3): Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",,,,,,100.0,,,306,306,
Not yet,807,,https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ,"Brussels, Flanders, and Wallonia (phase 4): Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",,,,,,100.0,,,306,306,
Not yet,808,,https://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-ELISA.pdf  ,"Brussels, Flanders, and Wallonia (phase 5): Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",,,,,,100.0,,,306,306,
Not yet,900,,"https://cdn.shopify.com/s/files/1/0094/4698/1732/files/POCT_-_VR-11_Clinical_Study.pdf?v=1591354196 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038148/","Ticino (Cantonal Office), phase 1: Techno Genetics, Rapid Test SARS-CoV-2 IgM/IgG Gold, anti-nucleocapsid",,,,,,98.9,,,269,272,
Not yet,901,,"https://cdn.shopify.com/s/files/1/0094/4698/1732/files/POCT_-_VR-11_Clinical_Study.pdf?v=1591354196 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038148/","Ticino (Cantonal Office), phase 2: Techno Genetics, Rapid Test SARS-CoV-2 IgM/IgG Gold, anti-nucleocapsid",,,,,,98.9,,,269,272,
Not yet,902,,"https://cdn.shopify.com/s/files/1/0094/4698/1732/files/POCT_-_VR-11_Clinical_Study.pdf?v=1591354196 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038148/","Ticino (Cantonal Office), phase 3: Techno Genetics, Rapid Test SARS-CoV-2 IgM/IgG Gold, anti-nucleocapsid",,,,,,98.9,,,269,272,
Not yet,903,,"https://cdn.shopify.com/s/files/1/0094/4698/1732/files/POCT_-_VR-11_Clinical_Study.pdf?v=1591354196 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038148/","Ticino (Cantonal Office), phase 4: Techno Genetics, Rapid Test SARS-CoV-2 IgM/IgG Gold, anti-nucleocapsid",,,,,,98.9,,,269,272,
No,1000,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Jersey, phase 1: Healgen COVID-19 IgG/IgM rapid test cassettes",100,88.7,100,30,30,97.5,91.3,99.3,78,80,
Not yet,1100,,https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3355-a001.pdf,"Jersey, phase 2: CTK Biotech Onsite COVID 19 IgG/IgM rapid test kit",,,,,,98.8,93.3,99.8,79,80,
Not yet,1101,,https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3355-a001.pdf,"Jersey, phase 3: CTK Biotech Onsite COVID 19 IgG/IgM rapid test kit",,,,,,98.8,93.3,99.8,79,80,
Not yet,1200,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Munich, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Not yet,1201,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Munich, phases 2,3: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Not yet,1202,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Northern California, phase 3: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Not yet,1203,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Geneva, phase 4: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Not yet,1204,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Germany, national (Forsa), phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Not yet,1205,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Germany, national (Forsa), phase 2: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Not yet,1206,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Arizona, Maricopa County: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Yes,1207,,"https://www.mhlw.go.jp/content/10900000/000934787.pdf  [n-280, table 4 on page 6]  ,  https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html","Aichi + Fukuoka [phase 2], Tokyo + Miyagi + Osaka [phase 3]: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",79.5,,,105,132,99.80,99.69,99.88,10432,10453,
Yes,1208,,"https://www.mhlw.go.jp/content/10900000/000934787.pdf  [n-280, table 4 on page 6]  ,  https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html","Aichi + Fukuoka [phase 3], Tokyo + Miyagi + Osaka [phase 4]: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",77.4,,,178,230,99.80,99.69,99.88,10432,10453,
Not yet,1209,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,"Saarland, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",,,,,,99.80,99.69,99.88,10432,10453,
Not yet,1300,,https://journals.asm.org/doi/10.1128/JCM.02596-20,Denver: Vitros Ortho total Ig anti-spike,,,,,,100,99.4,100,605,605,
Not yet,1301,,https://journals.asm.org/doi/10.1128/JCM.02596-20,DeKalb and Fulton (CDC): Vitros Ortho total Ig anti-spike,,,,,,100,99.4,100,605,605,
Yes,1302,,n-82 (table S-5),"Northern California, phase 1: Vitros Ortho total Ig anti-spike (high cutoff)",80.6,64.0,91.8,,,100,63.1,100,,,
Not yet,1400,,https://journals.asm.org/doi/10.1128/JCM.02596-20,Connecticut: Vitros Ortho (not total) IgG anti-spike,,,,,,100,99.4,100,600,600,
Not yet,1500,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,New York City: DiaSorin SARS-CoV-2 S1/S2 IgG,,,,,,99.3,98.6,99.6,1082,1090,
Not yet,1501,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Lodi province: DiaSorin SARS-CoV-2 S1/S2 IgG,,,,,,99.3,98.6,99.6,1082,1090,
Not yet,1502,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Ohio: DiaSorin SARS-CoV-2 S1/S2 IgG,,,,,,99.3,98.6,99.6,1082,1090,
No,1600,,n-82 (table S-5),"Northern California, phase 2: Vitros Ortho total Ig anti-spike (low cutoff), AND in-house anti-spike IgG ELISA",88.9,73.9,96.9,,,see note to the right,,,,,"treat specificity as a product of both tests (""VITROS"" and ""ELISA IgG"" in table S-5 of n-82); uses the lower value for sensitivity between the two assays (lack data to adjust for seroreversion for the ELISA IgG)"
Not yet,1700,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Geneva, phase 3: Elecsys Anti-SARS-CoV-2 Roche spike",,,,,,,,,5990,5991,
Not yet,1701,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Geneva, phase 4: Elecsys Anti-SARS-CoV-2 Roche spike",,,,,,,,,5990,5991,
No,1800,,,"Grand Nancy: Euroimmun spike, Platelia SARS-CoV-2 Total Ab Assay nucleocapsid, Biosynex (positive on at least 2 out of 3)",see note to the right,,,,,see note to the right,,,,,"treat specificity as product of the 2 tests with the lower specificity (Euroimmune + Biosynex), treat sensitivity as equivalent to whichever seroreversion-adjusted sensitivity is lower between Euroimmune vs. Platelia (this implicitly pessmistically assumes Biosynex has the worst seroreversion-adjusted senstivity of the 3 assays)"
Not yet,1900,,"n-138 , https://academic.oup.com/jid/article/222/9/1452/5885163",Netherlands phase 1: in-house anti-spike assay,,,,,,,,,399,404,
Not yet,1901,,"n-138 , https://academic.oup.com/jid/article/222/9/1452/5885163",Netherlands phase 2: in-house anti-spike assay,,,,,,,,,399,404,
Not yet,1902,,"n-138 , https://academic.oup.com/jid/article/222/9/1452/5885163",Netherlands phase 3: in-house anti-spike assay,,,,,,,,,399,404,
Not yet,1903,,"n-138 , https://academic.oup.com/jid/article/222/9/1452/5885163",Netherlands phase 4: in-house anti-spike assay,,,,,,,,,399,404,
Not yet,1904,,"n-138 , https://academic.oup.com/jid/article/222/9/1452/5885163",Netherlands phase 5: in-house anti-spike assay,,,,,,,,,399,404,
Yes,2000,,https://www.fda.gov/media/137493/download,"USA national, COVIDVu, phase 1: BioRad Platelia Total Antibody nucleocapsid",60.6,,,77,127,99.3,,,596,600,
Yes,2001,,https://www.fda.gov/media/137493/download,"California, COVIDVu: BioRad Platelia Total Antibody nucleocapsid",65.0,,,13,20,99.3,,,596,600,
Yes,2002,,https://www.fda.gov/media/137493/download,"DeKalb and Fulton counties, COVIDVu: BioRad Platelia Total Antibody nucleocapsid",66.7,,,34,51,99.3,,,596,600,
Not yet,2003,,https://www.fda.gov/media/137493/download,King County: BioRad Platelia Total Antibody nucleocapsid,,,,,,99.3,,,596,600,
Not yet,2004,,https://www.fda.gov/media/137493/download,"USA national, COVIDVu, phase 2: BioRad Platelia Total Antibody nucleocapsid",,,,,,99.3,,,596,600,
Yes,2005,,https://www.fda.gov/media/137493/download,"Georgia, COVIDVu: BioRad Platelia Total Antibody nucleocapsid",66.7,,,34,51,99.3,,,596,600,
Not yet,2100,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,Dallas + Tarrant: Abbott Alinity i SARS-CoV-2 IgG nucleocapsid,,,,,,99.0,94.6,99.8,99,100,
No,2200,,"n-206 , n-207 (insufficient evidence on seroreverion in tables S1 to S3)",Placer et al.: Stanford Health Care RBD ELISA,88.6,,,117,132,99.7,,,396,397,
No,2300,,n-57,Orange County: Coronavirus antigen microarray (CoVAM),93.9,,,93,99,100.0,,,88,88,
No,2400,,https://www.nature.com/articles/s41467-020-18848-0 (cited from n-23),Stockholm County: in-house dual-S anti-spike,99.2,,,241,243,99.8,,,441,442,
No,2500,,https://www.medrxiv.org/content/10.1101/2020.11.05.20226449v5.full-text,"Vienna: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid, Euroimmun spike, in-house neutralization assay (positive on multiple, including the neutralizaton assay)",93.8,,,60,64,100.0,,,1117,1117,
No,2501,,https://www.medrxiv.org/content/10.1101/2020.11.05.20226449v5.full-text,"Austria, national: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid, Euroimmun spike, in-house neutralization assay (positive on multiple, including the neutralizaton assay)",93.8,,,60,64,100.0,,,1117,1117,
Not yet,2600,,"https://journals.asm.org/doi/10.1128/JVI.01828-20 , https://link.springer.com/article/10.1007/s00038-020-01494-0","Fribourg, phase 1: SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)",,,,,,99.7,,,363,364,
Not yet,2601,,"https://journals.asm.org/doi/10.1128/JVI.01828-20 , https://link.springer.com/article/10.1007/s00038-020-01494-0","Fribourg, phase 2: SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)",,,,,,99.7,,,363,364,
Not yet,2602,,"https://journals.asm.org/doi/10.1128/JVI.01828-20 , https://link.springer.com/article/10.1007/s00038-020-01494-0","Neuchâtel, phase 1: SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)",,,,,,99.7,,,363,364,
Not yet,2603,,"https://journals.asm.org/doi/10.1128/JVI.01828-20 , https://link.springer.com/article/10.1007/s00038-020-01494-0","Neuchâtel, phase 2: SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)",,,,,,99.7,,,363,364,
Not yet,2604,,"https://journals.asm.org/doi/10.1128/JVI.01828-20 , https://link.springer.com/article/10.1007/s00038-020-01494-0","Neuchâtel, phase 3: SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)",,,,,,99.7,,,363,364,
Not yet,2605,,"https://journals.asm.org/doi/10.1128/JVI.01828-20 , https://link.springer.com/article/10.1007/s00038-020-01494-0","Vaud, phase 1: SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)",,,,,,99.7,,,363,364,
Yes,2700,,n-78,"Holyoke: Massachusetts General Hospital, anti-spike ELISA",66.7,,,12,18,99.5,,,1541,1548,
No,2800,,https://sph.nus.edu.sg/wp-content/uploads/2020/06/COVID-19-Science-Report-Diagnostics-1-Jun_updated.pdf,Cantabria: Hangzhou Clongene IgM/IgG rapid test,97.4,,,75,77,98.9,,,89,90,
No,2900,,https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3277-a001.pdf,Torrejón de Ardoz: Testsealabs COVID-19 IgG IgM rapid test,83.3,,,25,30,92.5,,,74,80,
Not yet,3000,,https://web.archive.org/web/20200623000020/https://www.norrbotten.se/publika/lg/kom/Corona/Rapport%20-%20f%c3%b6rekomst%20av%20antikroppar/F%c3%b6rekomst%20av%20antikroppar%20mot%20covid-19%20i%20Norrbottens%20befolkning%20maj%202020%20-%20Region%20Norrbotten%20rapport%20200618.pdf,"Norrbotten County: Abbott Architect IgG, re-test positives with Euroimmun anti-spike (must be positive on both) ",,,,,,,,,200,200,
Yes,3100,,"n-172 , https://sam.lrv.lt/uploads/sam/documents/files/KORONA/Serologini%C5%B3%20tyrim%C5%B3%20naudojimo%20rekomendacijos%20Versija_1.pdf (from n-25)","Lithuania, 6 cities and municipalities: AMP Rapid Test SARS-CoV-2 IgG/IgM",50.0,,,6,12,99.4,96.6,99.9,,,
Yes,3300,,https://www.fda.gov/media/137493/download,"USA, Houston: BioRad Platelia Total Antibody nucleocapsid + in-house ELISA IgG anti-spike (positive on either)",85.3,,,29,34,99.3,,,596,600,
Yes,3400,,"n-174 , https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance",Los Angeles County: Luminex xMAP for spike and nucleocaspid (Los Angeles study used RBD portion),97.0,90.3,99.1,,,99.3,98.3,99.7,599,603,
Yes,3500,,n-178,Hillsborough County: Mount Sinai RBD ELISA (New York),96.8,,,122,126,94.1,,,,,
Not yet,3600,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Puerto Rico, phase 1: for IgM - Abbott AdvisefDx IgM on ALINITY i anti-spike; for IgG - Abbott SARS-CoV-2 IgG on ALINITY i anti-nucleocapsid",see note to right,,,,,99.0,94.6,99.8,99,100,"use seroreversion curve for IgG assay since it has substantial seroreversion + vast majority of positive samples are IgG+, specificity is based on IgG assay for similar reason"
Not yet,3601,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Puerto Rico, phase 2: for IgM - Abbott AdvisefDx IgM on ALINITY i anti-spike; for IgG - Abbott SARS-CoV-2 IgG on ALINITY i anti-nucleocapsid",see note to right,,,,,99.0,94.6,99.8,99,100,"use seroreversion curve for IgG assay since it has substantial seroreversion + vast majority of positive samples are IgG+, specificity is based on IgG assay for similar reason"
Not yet,3700,,https://journals.asm.org/doi/epub/10.1128/Spectrum.01131-21,"Finland, phase 1: in-house THL Finland FMIA anti-spike assay",,,,,,100,99.1,100,402,402,
Not yet,3701,,https://journals.asm.org/doi/epub/10.1128/Spectrum.01131-21,"Finland, phase 2: in-house THL Finland FMIA anti-spike assay",,,,,,100,99.1,100,402,402,
Not yet,3800,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Tokyo, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3801,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Tokyo, phase 2: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3802,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Osaka, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3803,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Osaka, phase 2: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3804,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Miyagi, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3805,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Miyagi, phase 2: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3806,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"South Korea, phase 2: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3807,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"South Korea, phase 3: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3808,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"South Korea, phase 4: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3809,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Aichi, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3810,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Fukuoka, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3811,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"South Korea, phases 1-4: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid AND Abbott Architect IgG (positive on both tests)",see note to right,,,,,see note to right,,,,,"treat sensitivity as equivalent to Abbott (due to seroreversion), treat specificity as a product of the specificity of both tests"
Not yet,3900,,n-169,"Canada, national (Ab-C), phase 1: Sinai Health (Toronto) anti-spike ELISA, strict cutoff",,,,,,99.12,,,,339,
Not yet,4000,,https://www.medrxiv.org/content/10.1101/2021.10.25.21265476v1.full,"Canada, national (Ab-C), phase 2: Sinai Health (Toronto) anti-spike anti-RBD anti-nucleocapsid ELISA, lenient cutoff",,,,,,99.1,,,,554,
Not yet,4100,,,"Ohio: Abbott Architect IgG, OR Diasorin Liaison S1/S2 spike IgG, OR EDI Novel coronavirus COVID19 IgG anti-nucleocapsid (positive on at least 1 of)",see note to right,,,,,99.8,99.1,99.97,623,624,"treat sensitivity as equivalent to Diasorin with seroreversion (since Diasorin has the lowest seroreversion), treat specificity as equivalent to EDI since most positive samples were EDI positive"
Not yet,4200,,,"Iceland, greater Reykjavik area: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM, OR Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD (positive on either test)",see note to right,,,,,99.80,99.69,99.88,10432,10453,use seroreversion-adjusted sensitivity for whichever assay has higher sensitivity; used specificity for Roche since it's lower specificity
Not yet,4300,,,"Slovenia, phase 1: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM, AND Elecsys Anti-SARS-CoV-2 Roche spike",see note to right,,,,,see note to right,,,,,use seroreversion-adjusted sensitivity for whichever assay has lower sensitivity; treat specificity as a product of the specificity of test
Not yet,4301,,,"Slovenia, phase 2: Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM, AND Elecsys Anti-SARS-CoV-2 Roche spike",see note to right,,,,,see note to right,,,,,use seroreversion-adjusted sensitivity for whichever assay has lower sensitivity; treat specificity as a product of the specificity of test
No,4400,,https://academic.oup.com/ije/article/50/2/410/6146069#247859055  [section S2],"Los Angeles County, phase 1: Premier Biotech COVID-19 IgG/IgM Rapid Test anti-RBD",85.56,79.69,90.26,,,99.53,99.24,99.73,,,
Not yet,4500,,n-82 (table S-5),"Northern California, phase 3: Vitros Ortho total Ig anti-spike (low cutoff), AND Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM ",see note to right,,,,,see note to right,,,,,"treat specificity as a product of the specificity of test (VITROS and Roche in table S-5 of n-82), use seroreversion-adjusted sensitivity of the assay with lower sensitivity"
No,4600,,"n-253 , https://www.nature.com/articles/s41598-020-76913-6#Sec14  (figure S7)","California, 7 counties, phase 1: Enable’s ADAP SARS-CoV-2 total antibody anti-nucleocapsid",,,,20,20,,,,100,100,
No,4700,,https://www.nature.com/articles/s41598-020-76913-6#Sec14,"California, 7 counties, phase 1: Enable’s ADAP SARS-CoV-2 total antibody anti-spike, OR Enable’s ADAP SARS-CoV-2 total antibody anti-spike",100,89,100,31,31,100,95,100,80,80,
Not yet,4800,,https://www.frontiersin.org/articles/10.3389/fmicb.2020.628281/full,Yokohama: Tosoh anti-nucleocapsid total Ig with AIA-CL1200 ,,,,,,100,99.63,100,1000,1000,
Not yet,4900,,https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Ireland: Abbott Architect IgG, then re-test positives and borderline samples with Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",see note to right,,,,,99.6,99.0,99.9,1066,1070,treat sensitivity and specificity as equivalent to Abbott since it's used for screening and is more prone to seroreversion than Wantai
Yes,10000,,"n-261 (table 1)  ,  n-264 (for ""at least 2 out of 3 antigens"" and table 1)","Canada, national (CCAHS): CCAHS ELISA anti-spike anti-RBD anti-nucleocapsid (positive on at least 2 out of 3)",79.3,,,115,145,100.0,,,560,560,
Not yet,10100,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phase 1: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
Not yet,10101,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phase 2: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
Not yet,10102,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phase 3: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
Not yet,10103,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phase 4: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
Not yet,10104,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phase 5: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
Not yet,10105,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phase 6: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
Not yet,10106,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phase 7: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
Not yet,10107,,via: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance,"Arkansas, phases 2,5,7: Beckman ACCESS SARS-CoV-2 anti-RBD",,,,,,99.6,99.2,99.8,1395,1400,
No,10200,,https://www.nature.com/articles/s41598-021-97423-z  [n-287],"Jefferson County, phase 1: in-house Jefferson County anti-spike IgG",100,,,38,38,98.8,,,79,80,
No,10201,,https://www.nature.com/articles/s41598-021-97423-z  [n-287],"Jefferson County, phase 2: in-house Jefferson County anti-spike IgG",100,,,38,38,98.8,,,79,80,
No,10202,,https://www.nature.com/articles/s41598-021-97423-z  [n-287],"Jefferson County, phase 3: in-house Jefferson County anti-spike IgG",100,,,38,38,98.8,,,79,80,
No,10203,,https://www.nature.com/articles/s41598-021-97423-z  [n-287],"Jefferson County, phase 4: in-house Jefferson County anti-spike IgG",100,,,38,38,98.8,,,79,80,
No,10300,,http://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-Rapid-Test.pdf,"Czech Republic, Brno: Wantai rapid test, SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",94.7,,,125,132,98.9,,,268,271,
No,10301,,http://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-Rapid-Test.pdf,"Czech Republic, Prague: Wantai rapid test, SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",94.7,,,125,132,98.9,,,268,271,
No,10302,,http://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-Rapid-Test.pdf,"Czech Republic, Litomerice: Wantai rapid test, SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",94.7,,,125,132,98.9,,,268,271,
No,10304,,http://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-Rapid-Test.pdf,"Czech Republic, Olomouc: Wantai rapid test, SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",94.7,,,125,132,98.9,,,268,271,
No,10305,,http://www.ystwt.cn/wp-content/uploads/2020/05/Brochure-Wantai-SARS-CoV-2-Ab-Rapid-Test.pdf,"Czech Republic, Litovel and Uničov: Wantai rapid test, SARS-CoV-2 Total Antibody, IgG IgM (against RBD)",94.7,,,125,132,98.9,,,268,271,
Not yet,10400,,https://www.ijidonline.com/article/S1201-9712(20)30198-3/fulltext,Utsunomiya: YHLO iFlash SARS CoV-2 (spike + nucleocapsid),,,,,,90.9,,,30,33,